StockData
Zenas BioPharma, Inc. logo

Zenas BioPharma, Inc. (ZBIO) company profile

ZBIONasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 1/30
$27.75−0.18 (-0.64%)

Close on Nov 17, 2026Market cap $1.81BP/E –Yield –

About Zenas BioPharma

Pharmaceutical Preparations, SIC 2834

Zenas is a clinical-stage biopharmaceutical company that develops therapies for patients with autoimmune and inflammatory diseases. It acquires and develops product candidates directed at immune targets, without having any approved commercial products or sales revenue. Its lead candidate, obexelimab, is a monoclonal antibody that inhibits B-cell activity without cell destruction for conditions including immunoglobulin G4-related disease, relapsing multiple sclerosis, and systemic lupus erythematosus. The company also advances orelabrutinib for progressive forms of multiple sclerosis, along with early-stage candidates ZB021 and ZB022. Its end users are patients suffering from autoimmune conditions.

The provided text does not disclose the company's headquarters location. Operationally, the firm conducts clinical trials internationally across several countries, including the United States, the United Kingdom, Hungary, Poland, the Czech Republic, and Slovakia, dosing hundreds of clinical subjects. It maintains worldwide development rights for select pipeline assets while partnering with pharmaceutical companies across regional markets, including greater China and parts of the Asia-Pacific region.

Summary of the business section of Zenas BioPharma's latest annual report, written by StockData.

Company profile

Company

Legal name
Zenas BioPharma, Inc.
Headquarters
Waltham, MA
Address
852 Winter Street, Suite 250 02451
Phone
(857) 271-2954
Employees
167, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Ernst & Young LLP, Boston, Massachusetts

Stock & identifiers

Ticker
ZBIO
Exchange
Nasdaq
IPO date
Sep 13, 2024
Shares outstanding
65M, Jul 31, 2026
Public float
$259.30M, Jun 30, 2025
Filer category
<br>Emerging growth company
SEC CIK
1953926
CUSIP
98937L105
ISIN
US98937L1052
FIGI
BBG01J1MG9D6
Share class FIGI
BBG01J1MG9F4
EIN
00-0000000

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Leon O. Moulder JrSee Remarks, Director520,083
Moltke Lisa vonSee Remarks–
Joseph L. FarmerSee Remarks974
Jennifer A. FoxSee Remarks1,592
Orlando OliveiraSee Remarks–
Christy J. OligerDirector–
John J. OrloffDirector–
Patrick G. EnrightDirector1,844,659
Jason Raleigh NunnDirector3,119,959
Patricia L. AllenDirector19,860
James P. BoylanDirector–
Hongbo LuDirector426,736
Funds Management LLC FairmountDirector1,892,806
Tomas KiselakDirector2,359,025
Healthcare Fund II L.P. FairmountDirector287,915
Peter Evan HarwinDirector2,209,025
Ting XiaoDirector10,000

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusOption awardsIncentive payOtherTotalvs. prior year
Leon O. Moulder, Jr.
Founder, Chief Executive Officer and Chairman
$520.00K–$3.77M$371.80K–$4.66M-77%
Joseph L. Farmer
President and Chief Operating Officer
$520.00K–$1.65M$336.70K$20.80K$2.53M-58%
Lisa von Moltke, M.D.
Head of Research and Development and Chief Medical Officer
$411.67K$347.90K$2.74M––$3.50M–

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Sep 13, 2024
Offer price
$17.00
Securities offered
13,235,294
Gross proceeds
$225.00M
Exchange
Nasdaq
First trading day
Sep 13, 2024
First-day close
$18.15+6.8%
Lock-up ends (est.)
Mar 12, 2025

“The initial public offering price is $17.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of February 28, 2026, we had 167 full-time employees, consisting of clinical, scientific, development, medical affairs, technical operations, regulatory, finance, legal and operational personnel.”

Corporate history

Events identified from SEC filings

DateEventDetails
Sep 2, 2025Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Sep 13, 2024IPOInitial public offering priced (424B4 prospectus)
Sep 10, 2024ListingRegistration of securities on an exchange (Form 8-A)
Nov 15, 2022Name changeName changed from Zenas BioPharma (Cayman) Ltd to Zenas BioPharma, Inc.

See a number that looks wrong?